Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1993-11-16
|
pubmed:abstractText |
This clinical trial, which was composed of 1,031 adults undergoing cardiac operations, compared the efficacy of a single dose of 1 g of ceftriaxone with a 48-our regimen consisting of flucloxacillin and gentamicin. There was no significant difference (p = 0.89) in the overall incidence of major infections: 30 of 515 patients (5.8%; 95% confidence interval, 5.4% to 6.2%) taking ceftriaxone and 29 of 516 patients (5.6%; 95% confidence interval, 5.2% to 6.0%) taking flucloxacillin and gentamicin. Subgroup analyses, with a lower statistical power, failed to show a significant difference between patients who received ceftriaxone and those who received flucloxacillin/gentamicin: major sternal wound infections arose in 2.7% of the patients taking ceftriaxone versus 1.6% in those on the 48-hour regimen (p = 0.20) and major limb wound infections arose in 4.2% and 5.4%, respectively (p = 0.44). Single-dose prophylaxis was associated with fewer intravenous administrations (864 doses versus 9,570 doses) and cost less (A$17,248 versus A$78,510). Although the regimen that included gentamicin was associated with the greatest biochemical impairment of renal function, the overall toxicity for both groups was low. We conclude that a single dose of ceftriaxone provided cost-efficient prophylaxis for adults undergoing cardiac operations when compared with a 48-hour regimen of gentamicin and flucloxacillin. The general principle revealed by our data is that the short-term administration of an appropriate antibiotic regimen represents optimal prophylaxis for patients undergoing cardiac procedures.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0003-4975
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
56
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
916-22
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8215669-Adolescent,
pubmed-meshheading:8215669-Adult,
pubmed-meshheading:8215669-Aged,
pubmed-meshheading:8215669-Aged, 80 and over,
pubmed-meshheading:8215669-Cardiac Surgical Procedures,
pubmed-meshheading:8215669-Ceftriaxone,
pubmed-meshheading:8215669-Cost-Benefit Analysis,
pubmed-meshheading:8215669-Drug Therapy, Combination,
pubmed-meshheading:8215669-Female,
pubmed-meshheading:8215669-Floxacillin,
pubmed-meshheading:8215669-Gentamicins,
pubmed-meshheading:8215669-Humans,
pubmed-meshheading:8215669-Male,
pubmed-meshheading:8215669-Middle Aged,
pubmed-meshheading:8215669-Premedication,
pubmed-meshheading:8215669-Surgical Wound Infection
|
pubmed:year |
1993
|
pubmed:articleTitle |
Antibiotic prophylaxis in cardiac operations.
|
pubmed:affiliation |
Division of Surgery, Royal Perth Hospital, Australia.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|